FDA approved Descovy in at-risk adults and adolescents for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.
Read more: FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic